Trial Profile

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjectives With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PI 2620 (Primary)
Indications Alzheimer's disease; Mild cognitive impairment
Focus Diagnostic use

Most Recent Events

01 Sep 2023 This protocol has been amended as above-1)time frame of primary endpoint has been changed from 0-90 to 60-90 minutes post injection.
04 Aug 2022 Status changed to completed, according to Results presented at the Alzheimer's Association International Conference 2022
04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com